Opera News

Opera News App

Good News For All Covid-19 Patients

KayWealth
By KayWealth | self meida writer
Published 9 months ago - 18930 views

According to the report released by Sky News on Thursday, 16 July 2020. Oxford vaccine could provide double protection. The vaccine being developed at Oxford, is one of the leading contenders in the global race to protect against coronavirus.  

Researchers at the University of Oxford are convinced they have made a huge breakthrough, after many months in the development of a vaccine for COVID-19. Human trials are reported to have shown huge promising results, after their team discovered the vaccine could possibly provides "double protection" against COVID-19.

Here is the screenshot of Sky News report:

In addition, David Carpenter, the Chairman of Berkshire Research Ethics Committee, which approved the Oxford trial has stated that, if everything goes well, the vaccine could be fairly widely available around September.

This encouraging early results from clinical trials have raised hope. The race to create a COVID-19 vaccine is certainly accelerating. Oxford vaccine is designed to stimulate two parts of the immune systems, producing neutralising antibodies and T-cells, both of which can play a key in preventing viral infection. 

BBC News also revealed that, early results from two trials in the US, run by the Pharmaceutical Giant Pfixer and Biotech Company Moderna, suggest both their vaccines could produce a good immune response in volunteers. 

India Today, also captured the news of the latest development. As the world battles the COVID-19 pandemic, India Today reveals that 35 companies and academic institutions across the world, are racing against time to create vaccine for the virus. 

India Times also released a video that shows how Oxford vaccine is in final phase. Here is the link to the Facebook video they uploaded:

https://www.facebook.com/indiatimes/videos/330522985012718/

Are you wondering, who are the people funding the research? Here is your answer.

Amidst the COVID-19 pandemic, Zuckerberg donated $25 million to a Bill and Melinda Gates Foundation-backed accelerator that is searching for treatments for the disease. He also announced $25 million in grants to support local journalism that was impacted by the pandemic, and $75 million in advertisement purchases in local newspapers by Facebook, Inc.

On 15 April 2020, The Bill & Melinda Gates Foundation announced an expansion of its funding for the global response to COVID-19. The increase includes an additional $150 million of grant funding, plus a commitment to leverage the resources of the foundation’s Strategic Investment Fund, which could be deployed to catalyze the rapid procurement of essential medical supplies and help life sciences companies secure financing to produce COVID-19 products. 

In announcing the funding, the foundation called on world leaders to unite in a global response to COVID-19 to ensure equitable access to diagnostics, treatments, and vaccines.

Bill Gates once said and I quote, "One of our first big investments was to an organization called Gavi, the Vaccine Alliance. Since 2000, Gavi and partners have immunized more than 760 million children, saving over 13 million lives. And now, Gavi has a new effort underway to purchase COVID-19 vaccines for lower-income countries as soon as they are available." 

Content created and supplied by: KayWealth (via Opera News )

Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform

YOU MAY LIKE

Man Surprises Dying Girlfriend By Fulfilling Her Last Wish (PICS+VIDEO)

6 minutes ago

0 🔥

Man Surprises Dying Girlfriend By Fulfilling Her Last Wish (PICS+VIDEO)

Checkout These Shoes That Were Built Like Human Legs. Can You Wear It?

20 minutes ago

0 🔥

Checkout These Shoes That Were Built Like Human Legs. Can You Wear It?

Check Out This Spider That Can Cause Erection If It Bites You.

22 minutes ago

0 🔥

Check Out This Spider That Can Cause Erection If It Bites You.

Daily Devotional: Turn Your Loss Into Gain Part Two

28 minutes ago

1 🔥

Daily Devotional: Turn Your Loss Into Gain Part Two

Today's Headline: "Anyone Who Neglects This Warning Should Prepare To Join His Ancestors"-IPOB

52 years ago

0 🔥

Today's Headline:

Popular TV Presenter, Rachel Backam is dead

56 minutes ago

20 🔥

Popular TV Presenter, Rachel Backam is dead

In Nigeria farmers make money from these farm crops.

1 hours ago

6 🔥

In Nigeria farmers make money from these farm crops.

Fear grabs residents as Boko Haram attack Gombe state and Borno states

1 hours ago

330 🔥

Fear grabs residents as Boko Haram attack Gombe state and Borno states

Harrison Shares Video Of Ada Jesus Receiving Treatment In Hospital, See Her Current Condition

1 hours ago

270 🔥

Harrison Shares Video Of Ada Jesus Receiving Treatment In Hospital, See Her Current Condition

Reactions as UNIUYO student beats lecturer on the chest more than once in class

1 hours ago

190 🔥

Reactions as UNIUYO student beats lecturer on the chest more than once in class

COMMENTS

View all comments